Zhou J, Jensen S M, Steinberg S M, Mulshine J L, Linnoila R I
Biomarkers and Prevention Research Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.
Lung Cancer. 1996 Feb;14(1):85-97. doi: 10.1016/0169-5002(95)00514-5.
In an immunocytochemical study of sputum, two antibodies, including a mouse monoclonal antibody (703D4) to a 31 kDa protein (p31) antigen, have been previously shown to detect lung cancer earlier than routine cytomorphology or chest X-ray. To understand the basis of p31 expression, the distribution of this antigen in the respiratory epithelium of individuals known to have lung cancer was mapped. These individuals are likely to demonstrate extensive changes throughout the epithelium due to field cancerization. p31 immunoreactivity was examined in primary tumors and surrounding non-neoplastic lungs containing both histologically normal and abnormal areas obtained from 28 Stage I non-small cell lung cancer (NSCLC) patients. Distribution and intensity of p31 expression was scored in three lung compartments (bronchi, bronchioli, alveoli). While p31 was present in histologically unremarkable bronchial and bronchiolar epithelium, no expression was detected in bronchi or bronchioli containing histologic abnormalities. Furthermore, in the peripheral lung p31 staining was frequently observed in alveolar type II cells and was most commonly detected in reactive, hyperplastic type II cells. When p31 immunoreactivity was correlated with clinicopathological features, a statistically significant increase in p31 expression was found both in bronchioli and alveoli of older individuals a well as in bronchioli of patients with most extensive smoking exposure. We conclude that p31 expression occurs in both non-neoplastic and neoplastic epithelium of the human respiratory tract. The increased expression of p31 in the peripheral lung may be potentially informative as to what critical cell populations are involved in the development of invasive cancers. Moreover, this study provides a model approach for analysis of the nature of early epithelial changes leading to the development of lung cancer.
在一项痰液免疫细胞化学研究中,先前已证明两种抗体,包括一种针对31 kDa蛋白(p31)抗原的小鼠单克隆抗体(703D4),比常规细胞形态学或胸部X光更早检测到肺癌。为了解p31表达的基础,绘制了已知患有肺癌个体的呼吸道上皮中该抗原的分布图。由于场癌化,这些个体可能在整个上皮中表现出广泛变化。对28例I期非小细胞肺癌(NSCLC)患者的原发性肿瘤以及包含组织学正常和异常区域的周围非肿瘤性肺组织进行了p31免疫反应性检测。在三个肺区室(支气管、细支气管、肺泡)中对p31表达的分布和强度进行评分。虽然p31存在于组织学上无异常的支气管和细支气管上皮中,但在含有组织学异常的支气管或细支气管中未检测到表达。此外,在周边肺组织中,p31染色经常在II型肺泡细胞中观察到,最常见于反应性、增生性II型细胞中。当p31免疫反应性与临床病理特征相关联时,发现老年个体的细支气管和肺泡以及吸烟暴露最广泛的患者的细支气管中p31表达有统计学意义的增加。我们得出结论,p31表达发生在人类呼吸道的非肿瘤性和肿瘤性上皮中。周边肺组织中p31表达的增加可能对侵袭性癌症发展中涉及哪些关键细胞群体具有潜在的信息价值。此外,本研究为分析导致肺癌发生的早期上皮变化的性质提供了一种模型方法。